By Headlines Team

One of the most common points of confusion for patients exploring ketamine-based treatments is the relationship between intravenous ketamine infusion and esketamine nasal spray. Both involve ketamine-derived compounds, both work through the glutamate system, and both are used for treatment-resistant depression. But they are not the same treatment, and the differences between them are clinically meaningful in ways that affect which option is most appropriate for different patients.

Understanding these differences, and how a specialist psychiatric team approaches the choice between them, is increasingly relevant as both options have become more widely available in New York City.

The Pharmacological Relationship

Ketamine is a racemate, meaning it is a mixture of two mirror-image molecular forms known as enantiomers: the R-enantiomer and the S-enantiomer. Esketamine, the active ingredient in Spravato, is the pure S-enantiomer. The S-form binds more potently to the NMDA receptor than the R-form and is therefore effective at lower doses.

Intravenous ketamine infusion uses racemic ketamine, the mixture of both enantiomers, delivered directly into the bloodstream. Esketamine nasal spray uses only the S-enantiomer, delivered intranasally. Because of the different delivery routes, the pharmacokinetics differ: IV infusion produces more predictable blood levels and a faster onset of the dissociative experience, while intranasal delivery results in more variable absorption and a typically less intense acute experience.

Both produce antidepressant effects through the same primary mechanism. Both carry similar short-term safety considerations around dissociation, blood pressure changes, and sedation. The key differences lie in regulatory status, insurance coverage, clinical setting requirements, and the nature of the treatment experience.

Regulatory Status and Insurance Implications

This is perhaps the most practically significant difference for most patients. Esketamine nasal spray, sold as Spravato, is FDA-approved for treatment-resistant depression and for major depressive disorder with acute suicidal ideation. According to the FDA, Spravato must be used in conjunction with an oral antidepressant and administered under direct healthcare supervision in a certified facility. This regulatory approval means it has an established clinical evidence base, standardised dosing guidelines, and — critically — insurance coverage through most major commercial plans and Medicare and Medicaid for eligible patients.

Intravenous ketamine is not FDA-approved for psychiatric indications. Its use for depression is off-label, which means that the evidence base is substantial and widely accepted in clinical practice, but formal insurance coverage is much more limited. Most patients receiving IV ketamine do so on a self-pay basis, though some insurers do cover it in specific circumstances.

For patients who are cost-sensitive or who have insurance that covers Spravato but not IV ketamine, this distinction is decisive. For patients with the financial means to pursue either option or who have existing coverage for IV ketamine, the choice can be made on clinical grounds.

The Clinical Setting

Both treatments require administration in a supervised clinical setting and cannot be taken at home. The REMS requirements for Spravato mandate that it be administered in a certified healthcare facility with the capacity to monitor patients for at …read more

Source:: Social Media Explorer

Author: Aaron